Clinical trial · Observational
Fungal Infections in Patients With Hematological Malignancies
Fungal Infections In Patients With Hematological Malignancies In South Egypt Cancer Institute
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
\* Report the prevalence of fungal infections among patients with hematological malignancies in South Egypt Cancer Institute. \* Detect the most endemic fungal pathogen isolated from patients with hematological malignancies in South Egypt Cancer Institute. \*Antifungal susceptibility testing which guide the optimal approach to treat fungal infections. \* detection of resistant gene expression by real time PCR. \* Fungal genome sequencing analysis to determine the genetic back ground upon which mutation and resistance occur.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fungal Infection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| culture on Sabouraud's Dextrose Agar (SDA) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- identification of endemic fungal pathogen in patients with hematological malignancies south Egypt cancer institute.
- timeFrame
- one year study
- description
- Detect the most endemic fungal pathogen isolated from clinical sampels of patients with hematological malignancies in South Egypt Cancer Institute.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Immunocompromised adult patient with hematological malignancy , risky to fungal infection as * patients receiving cytotoxic or immunosuppressive therapy. Patients with prolonged and deep neutropenia. * patients exposed to prolonged use of antibiotic , prolonged Foley catheter drainage peripheral I.V catheters, corticosteroid use * patients have presentations of fungal infection such as pulmonary infections ( pneumonia , sinusitis). and disseminated infection manifested commonly as skin lesions or soft tissue involvement . Exclusion Criteria: * Non hematologicaly malignant patients . * Any contraindication regarding procedure as: * Local infection or distorted anatomy at the potential puncture site (eg, from previous surgical interventions,congenital or acquired malformations, or burns) * Severe peripheral vascular disease of the limb involved
References
Publications (0)
Data not yet available